Wolff Wiese Magana’s Evolent Health EVH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.3K Hold
3,000
0.01% 406
2026
Q1
$6.84K Hold
3,000
﹤0.01% 532
2025
Q4
$12K Hold
3,000
0.01% 412
2025
Q3
$25.4K Hold
3,000
0.01% 288
2025
Q2
$33.8K Sell
3,000
-57
-2% -$524 0.02% 236
2025
Q1
$28.9K Hold
3,057
0.02% 238
2024
Q4
$34.4K Hold
3,057
0.02% 234
2024
Q3
$86.5K Buy
3,057
+57
+2% +$1.47K 0.06% 148
2024
Q2
$57.4K Hold
3,000
0.05% 151
2024
Q1
$98.4K Hold
3,000
0.08% 115
2023
Q4
$99.1K Hold
3,000
0.09% 112
2023
Q3
$81.7K Hold
3,000
0.07% 147
2023
Q2
$90.9K Hold
3,000
0.07% 140
2023
Q1
$97.3K Hold
3,000
0.08% 138
2022
Q4
$84.2K Hold
3,000
0.07% 147
2022
Q3
$108K Hold
3,000
0.09% 156
2022
Q2
$92K Hold
3,000
0.07% 183
2022
Q1
$97K Hold
3,000
0.07% 191
2021
Q4
$83K Hold
3,000
0.05% 220
2021
Q3
$93K Hold
3,000
0.07% 204
2021
Q2
$63K Hold
3,000
0.04% 253
2021
Q1
$61K Hold
3,000
0.05% 246
2020
Q4
$48K Buy
+3,000
New +$39.7K 0.04% 269

Other funds holding EVH

Wolff Wiese Magana's EVH Position: Q2 2026 in Review

Wolff Wiese Magana held its Evolent Health (EVH) position steady in Q2 2026 at 3,000 shares worth $16.3K. The position accounts for 0.01% of the portfolio, ranked #406.

Wolff Wiese Magana first reported a position in EVH in Q4 2020 and has held it in 23 quarters since. The position peaked at $108K in Q3 2022. 14 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

  • Wolff Wiese Magana held 3,000 shares of Evolent Health worth $16.3K as of Q2 2026.
  • Wolff Wiese Magana left its Evolent Health share count unchanged in Q2 2026.
  • Evolent Health made up 0.01% of Wolff Wiese Magana's portfolio in Q2 2026, its #406 holding.
  • Wolff Wiese Magana first reported a position in Evolent Health in Q4 2020 and has held it in 23 quarters since.
  • Wolff Wiese Magana's Evolent Health position peaked at $108K in Q3 2022.
  • 14 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Wolff Wiese Magana's 13F filing for Q2 2026, filed 13 Jul 2026.